Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


China’s Healthcare Reform To Spur Vaccine Market Expansion

This article was originally published in PharmAsia News

Executive Summary

China recently unveiled its finalized healthcare reform plan (PharmAsia News, Apr. 8, 2009), which aims to make basic healthcare accessible for all its citizens in both urban and rural areas. The prevention-oriented reform will bring huge market opportunities for vaccine manufacturers. According to estimates, China's public healthcare expenditure will reach RMB 19.5 billion ($2.85 billion) in 2009, and RMB 26 billion ($3.8 billion) by 2011. At this growth rate, the vaccine sector is expected to increase more than 30 percent. With per capita healthcare expenditure rising, the nation will prioritize the usage of vaccines and pay for its application. As China's leading vaccine producer, Sinovac said it will benefit from the reform and is putting its focus to cater more to public interest. (Click here for more - Chinese language)

You may also be interested in...

China Issues Three-year Healthcare Reform Plan To Invest RMB 850 Billion

SHANGHAI - China issued its long-awaited three-year plan for its healthcare reform, and unveiled how the country will allocate RMB 850 billion ($124 billion) in the next three years

Veru Hopes To Position Enobosarm As Muscle-Protective In Weight-Loss Therapy

A selective androgen receptor modulator also being studied in metastatic breast cancer, enobosarm might offer potential as add-on therapy to GLP-1 agonists prescribed for weight loss, the Miami biotech asserts.

Medtech Connect Episode 10: Breaking Down The Transitional Coverage Of Emerging Technologies

In this episode, Medtech Insight regulatory reporter Hannah Daniel speaks to Washington Analysis vice president and senior healthcare analyst John Leppard about the Center for Medicare and Medicaid’s Transitional Coverage Of Emerging Technologies pathway, or TCET. He breaks down the pathway and discusses its pros and cons, as well as potential next steps for the agency. We also explore the history of breakthrough device coverage as well as the challenges for coverage of digital health devices.

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts